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Abstract 
Antiangiogenic treatment has recently become an integral part of modern cancer 
therapy targeting the vasculature of numerous aggressive malignancies including 
glioblastoma. There is preclinical evidence that antiangiogenic therapies promote 
glioma cell invasiveness.  
In clinical series, upon progression on antiangiogenic therapy with the VEGF-directed 
antibody bevacizumab (BEV), glioblastoma have been reported to display a more 
infiltrative pattern of recurrence. This distant spread at recurrence or progression and a 
gliomatosis cerebri-like growth pattern is best detectable on fluid attention inverse 
recovery (FLAIR) magnetic resonance images (MRI). The frequency of up to 20-30% of 
such a pattern in BEV-treated patients is higher than expected to occur without BEV. 
Older reports and common clinical knowledge estimate the frequency of diffuse or 
distant spread in recurrent glioblastoma at 10%. 
This observation stimulated two streams of research. One is to overcome this often 
insidious adverse effect of anti-angiogenic treatment, to optimize antiangiogenic 
therapies and to face this major challenge, integrating antiangiogenic with antiinvasive 
mechanisms into one combined treatment concept. The second is questioning a 
specific property of antiangiogenic therapy to induce diffuse or distant spread. Here, 
alternative hypotheses of increased awareness and better imaging as well as 
invasiveness being part of the natural course of the disease have been tested.  
Without doubt, migration and invasiveness are major obstacles to successful glioma 
therapy, notably local therapies, both in the natural course of the disease and in the 
concept of „evasive resistance“. However, clinical analyses of case series, matched 
pairs analyses and follow up on the BRAIN trial, which led to accelerated approval of 
BEV for recurrent glioblastoma in the United States, have not supported a specific 
propensity of BEV to induce diffuse growth or distant spread at recurrence.  
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Introduction 
The vascular endothelial growth factor (VEGF) antibody bevacizumab (BEV) has 
increased the repertoire of medical treatment options for patients with recurrent 
glioblastoma. Two uncontrolled phase II studies [1,2] were the basis for approval in the 
USA in May 2009 whereas the European Medial Agency (EMA) rejected approval in 
the EU [3]. In the US the rate of objective responses (RR) [4] was accepted as a 
denominator for clinical relevance posing increasing weight on magnetic resonance 
imaging (MRI) as a surrogate marker for treatment efficacy. Anti-VEGF/VEGF receptor 
(VEGFR) compounds [5] at least as part of their mode of action induce normalization of 
the vasculature [6] by inhibiting pathological proliferation of endothelial cells and 
immature vessel formation. Secondly, as early as 1-2 days after initiation of therapy, a 
reduction of the permeability of the blood-brain-barrier results in decreased contrast 
enhancement and edema and high objective radiological response rates of 25-60% 
[1,2,5,7,8]. The makeup of the current as well as novel revised response criteria do not 
allow to easily differentiate this effect on the barrier permeability from a direct antitumor 
effect [9,10]. So far, the unprecedented high response rates these agents produced in 
recurrent glioblastoma have not translated into a survival benefit of the same 
magnitude [11].  
Accumulating evidence incriminates therapeutically active antiangiogenic therapies to 
elicit an adaptive-evasive response involving augmented tumor cell invasion or 
increased dissemination and distant metastasis in various neoplasias both inside and 
outside the central nervous system (CNS) [12,13]. Preclinical studies have indicated 
that anti-VEGF therapy may increase the tendency of tumor cells to invade by co-
opting existing blood vessels [14,15]. For the molecular mechanisms involved two 
major hypotheses are discussed. Antiangiogenic therapy increases hypoxia and 
acidosis, which activates survival signals, like the mammalian target of rapamycin 
(mTOR)/protein inositol 3-kinase pathway, and promotes glycolytic energy metabolism 
and autophagy [16]. Alternatively or in addition, antiangiogenic therapy with targeted 
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agents like antiangiogenic radiotherapy [17,18] induces specifically, and as an 
undesirable side effect, cell motility.  
For BEV, various patient series have suggested an increase in diffusely or distantly 
recurring tumors [11,19]. This gliomatosis-like phenotype or remote spread is best 
depicted on fluid-attenuated inversion recovery (FLAIR) MRI sequences [11]. 
Determination of the extent of this non-enhancing component of the tumor on the T2-
weighted and FLAIR image sequences is difficult because of the similar appearance of 
peritumoral edema, which also has a bright signal on T2-weighted or FLAIR MRI 
sequences. 
It may happen that despite persistent reduction in contrast enhancement an increase in 
non-enhancing T2 or FLAIR signal alterations suggestive of infiltrative tumor develops 
[11,19,20].  This dissociation is called “discordance” between the information gathered 
on T1+c and T2 images [20,21]. Amongst others this led to a reconsideration of the 
Macdonald criteria [9]. The response assessment criteria developed by the Response 
Criteria in Neurooncology Working Group (RANO) will qualitatively consider enlarging 
areas of non-enhancing tumor as evidence of tumor progression [10]. 
Here, the question whether anti-angiogenic treatments really enhance distant tumor 
spread compared with classical salvage regimens or the natural course of the disease 
is discussed based on the review of existing literature. To approach the topic of 
recurrence pattern analysis in glioma in the future, relevant preclinical paradigms have 
to be developed and working criteria for future assessment of recurrence patterns in 
the clinic need to be discussed.  
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Methods 
Principles 
To assess the impact of anti-VEGF/VEGFR treatments on the recurrence pattern in 
glioma, consecutive MRI (before, during and after treatment) have to be analyzed in 
T1-weighted sequences with contrast, T2-weighted or FLAIR sequences and possibly 
also diffusion-weighted images at certain, fixed intervals. Lack of stringent MRI follow-
up makes the comparison between different reports on recurrence patterns very 
difficult. This can be done on a case-by-case basis or group-wise. Also, uncontrolled 
series or controlled studies at different levels of control (matched pairs or randomized 
trial) can be used.  
 
Analysis of tumor location 
A group-wise analysis has been developed for the analysis of the recurrence pattern of 
glioblastoma patients treated within the EORTC 26981/22981/NCIC CE.3 registration 
trial for temozolomide. Briefly, mapping of lesions is performed by the experimenters 
without knowledge of the clinical features of the patients. The boundary of the tumor 
location at baseline and at follow-up is delineated using MRIcro software [22] or 
exported from the 3D-raw MRI data and mapped on the template MRI from the 
Montreal Neurological Institute (www.bic.mni.mcgill.ca/cgi/icbm_view) that is distributed 
with freely available software, MRIcro. The template scan provides various anatomical 
landmarks for precisely plotting the localization of the tumor if import of data is not 
feasible. Lesions are mapped onto the slices that correspond to the MNI z-coordinates 
using the identical or the closest matching transversal slices of each individual. Tumors 
are mapped for each individual, with separate tumor maps generated for the baseline 
and recurrence scan. The logic of the analysis is straightforward. First, tumor lesions 
for a patient group at baseline and lesions for this group at recurrence are defined on 
the same template image. Next, the lesions at baseline are added together, creating an 
overlap image showing the regions of involvement. The same is carried out for the 
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lesions at recurrence. Finally, the overlap image of the lesions at recurrence are 
subtracted from the lesion overlap image at baseline. This method creates an image 
that shows regions that are commonly damaged in the patient group at recurrence but 
are typically spared in this group at baseline (coded as positive values), regions 
specifically damaged at baseline (coded as negative values) and regions that are 
damaged/spared in equal proportions between the two stages (values near zero) [23].  
 
Criteria for the case-by-case analysis 
Although the group-wise analysis is an elegant measure analyzing a cohort rather than 
individual patients, it suffers from the mass effects of larger tumors on the normal 
anatomical structures. Hence, although interesting for the assessment of recurrence 
patterns in newly diagnosed glioblastoma [23], it may be less valuable in recurrent 
disease with a large tumor volume at baseline. Therefore, it may also be necessary to 
assess single patients. Criteria for the assessment are detailed in the Table. 
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Evidence of increased frequency of remote relapse with BEV treatment? 
There is concern from earlier clinical observations that anti-angiogenic treatment may 
prevent the formation of a tumor bulk, but may not be effective against progression in 
the infiltrative zone. Infiltrative growth is held responsible for morbidity and survival 
[11,24] and diffusely infiltrative recurrence [25] may escape classical T1+c MRI 
response assessments. In clinical series, upon progression on antiangiogenic therapy 
with the BEV, glioblastomas often displayed a more infiltrative pattern of recurrence. 
Preclinical data suggest vascular co-option as an escape mechanism to anti-
angiogenic treatments. This is challenged by the fact that the area infiltrated by these 
tumor satellites [8,14,26] may not exceed the area of the untreated control tumors. 
Further, treatment with anti-angiogenic agents nevertheless results in impressive 
effects on OS in animal models [8,15,27]. This allows the differential hypothesis of anti-
angiogenic therapy failing at the tumor-vascular interface, probably because of altered 
physiological, metabolic conditions in close proximity to the vessel. Norden et al. [20] 
looked at 55 BEV-treated and 19 control patients. Although they did not demonstrate a 
difference in recurrence patterns between both groups, they concluded that there might 
occur a relevant discordance between the T1+c and the FLAIR appearance of the 
recurrent BEV-treated tumors. They observed an increase in the FLAIR lesions 
especially in patients, which had at least a minor response on T1+c MRI sequences. 
This fact has supported the notion that in the era of anti-angiogenic treatments, 
contrast enhancement may not reliably signify tumor response. There is thus a need to 
account for the non-enhancing component of the tumor to accurately assess the 
efficacy of novel therapeutic modalities [9]. Further, in their work there was no 
difference in the rate of distant recurrences dependent on the fact whether BEV was 
given as a monotherapy or in conjunction with a chemotherapy. Of note, so far all 
attempts to combine BEV at recurrence of a glioma with another cytotoxic regimen 
failed to show additional benefit over the published efficacy data from the BRAIN trial, 
that is, that obtained with BEV alone. 
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No shift of recurrence pattern in BEV versus BEV plus CPT-11 treated patients: 
an analysis from the BRAIN trial 
The recurrence pattern analysis of the BRAIN trial was looking for a shift from local 
tumors to distant or diffuse recurrence when treated with BEV or BEV plus irinotecan. 
The analysis indicated that between 20-30% tumors recurred remotely. Further, a 
distant recurrence was not predictive for a poor outcome compared to patients with 
local recurrences [27]. Comparing BEV and BEV plus CPT-11 from the BRAIN trial,[1] 
there was even a larger shift in the recurrence pattern from local to distant or diffuse in 
the BEV+ irinotecan arm as compared to BEV alone [22]. This does not support the 
idea that additional chemotherapy may prevent the untoward switch of the tumor 
phenoptype to a more invasive growth pattern.  
 
Distant or diffuse recurrence may be a feature of late-stage glioma rather than a 
specific property of antiangiogenic treatments 
The clinical data looked at so far are not controlled, but either used historical 
comparisons or analyzed not the impact of BEV itself, but the differential effect of CPT-
11 plus BEV versus BEV alone as in the BRAIN trial. Others challenge the systematics 
of an analysis by providing results (distant/diffuse or local) for each step of a patients’ 
history with multiple recurrences, each with a risk of around 20% to be distant. Here, 
eventually each patient should suffer from a distant recurrence, arguing more for 
invasion belonging to the natural course of the disease rather than a specific 
phenomenon in anti-VEGF treated patients [28,29]. To determine the overall frequency 
of distant recurrences in BEV-treated patients as assessed by the outlined group-wise 
methodology [23], we analyzed MRI examinations of 112 patients prior to and at failure 
of BEV. The frequency of distant recurrences in this patient series was 23%. Of note, 
20% distant recurrences had been found in an analysis of the recurrence patterns at 
11 W. Wick et al.  
 DRAFT-final 
 
first progression of the non-BEV-containing EORTC 26981/22981/NCIC CE.3 trial [23] 
and prior data suggested a frequency of distant failure of between 20 and 30% with 
BEV [11,19,20]. Therefore, a controlled analysis should ask the question whether 
distant recurrences are more frequent in BEV-treated patients versus patients with 
similar clinical characteristics who have not been exposed to BEV or another anti-
angiogenic treatment in the observation period.  
In our set of patients analyzed, 20.5% (BEV) and 22.7% (non-BEV) had displayed 
distant recurrence according to the criteria (Table) at entrance to the recurrence pattern 
analysis performed to check for the BEV effect. In the study, distant or diffuse 
recurrences with the treatments of this analysis at recurrence were observed in 22% 
(10 of 44, BEV) and 18% (8 of 44, non-BEV) on T1+c and in 25% (11 of 44, BEV) and 
18% (8 of 44, non-BEV) on FLAIR sequences. In that analysis, the risk of distant or 
diffuse recurrence in matched pairs did not differ between BEV-containing and BEV-
free treatments [30]. These data in the BEV group and the methodology except for a 
lesser variance (< 2 cm instead of < 3 cm) in the definition of local recurrence and the 
addition of the group-wise analysis are consistent with the analysis of the BRAIN trial 
[1]. 
 
Translational imaging research in a controlled trial may provide a definite answer 
A major concern with anti-angiogenic treatments for glioblastoma is the hypothesis that 
these treatments transform a pro-angiogenic into a pro-migratory phenotype, resulting 
in more diffusely infiltrating tumors and finally more neurological morbidity after an 
initial phase of symptom relieve [25]. The therapeutic need in recurrent glioblastoma is 
evident from the published overall survival data in that situation, ranging from 5 to 10 
months. The role of BEV in brain tumors is not completely clear in the absence of 
phase III trials, neither is there proof for its superiority over any other cytotoxic 
treatment at recurrence. Even if considered efficacious the best data with BEV leave 
wide room for improvement and a systematic controlled evaluation of combinations 
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between BEV and cytotoxic agents is missing. Lomustine is used as control arm in 
ongoing phase II and III trials, but has limited efficacy in randomized phase III trials in 
the era with temozolomide in the first-line treatment [31]. This is true although in a 
recently completed phase III trial of the VEGFR-2 inhibitor cediranib, neither the drug 
nor the combination with lomustine was superior to lomustine alone, arguing against 
lomustine being an insufficient comparator for modern trial [32]. In addition, gliomatosis 
remains an undefined concern after BEV treatment. It may be a specific unwanted 
effect of BEV in some patients, but is also seen with conventional chemotherapy at 
recurrence. It will be interesting to clarify whether this is a specific class property of 
antiangiogenic agents or a phenomenon of later stage glioblastoma. Therefore, a 
careful assessment on how BEV and lomustine may contribute to the standard of care 
requires a careful well-built/ step-wise approach. 
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Conclusions 
Norden et al. [20] did not demonstrate a difference in recurrence patterns between 
BEV- and non-BEV-treated patients, but concluded that there might occur a relevant 
discordance between T1+c and FLAIR appearance of the BEV-treated tumors. An 
increase in the FLAIR lesions especially in patients demonstrating at least a minor 
response in T1+c was observed and finally added to the recognition that especially in 
the era of anti-angiogenic treatments, a reduction of contrast enhancement may not 
reliably signify tumor response. There was thus a need to account for the non-
enhancing component of the tumor to assist with the accurate assessment of the 
efficacy of novel therapeutic modalities. These data in addition to the debate around 
peudoresponse led in the set-up of a working group to initiate a discussion on the 
imaging criteria in glioma (RANO working group), which already published updated 
imaging criteria recognizing the problems discussed here. 
Second, the available clinical analyses argue against the propensity of BEV to induce 
clinically meaningful and T1+c MRI-negative invasiveness as demonstrated by FLAIR 
images. Distant tumor spread may instead be a result of increased awareness or 
prolonged survival in glioblastoma patients.  
Third, the relevance of diffusion weighted imaging (DWI) restrictions on MRI is unclear. 
They have been proposed as a novel pattern of progression under BEV treatment [23] 
In contrast, DWI restriction might also reflect an unusual response pattern [33]. DWI 
restriction occurred within the previously enhancing tumor volume and corresponded to 
atypical necrosis [34]. More unlikely, DWI restrictions may reflect vascular, ischemic 
complications of BEV treatment.  
Last, this data needs to be confirmed and methodologically expanded in the upcoming 
randomized trials, e.g., by the EORTC with strong imaging translational research. 
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